Search Clinical Trials | Vanderbilt-Ingram Cancer Center

Filter By:
Search by Keyword:

Displaying 91 - 100 of 230

Long-Term Follow-Up Study for Participants of Kite-Sponsored Interventional Studies Treated with Gene-Modified Cells

Multiple Cancer Types

Disease Sites: Hematologic, Leukemia, Lymphoma, Pediatric Leukemia, Pediatric Lymphoma

Phase: N/A

Investigator: Kassim, Adetola

NCTID: NCT05041309

Protocol No: VICCCTT2170

Learn More

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2 Related Genetic Alterations (MK-6482-015)

Multiple Cancer Types

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Disease Sites: Endocrine, Pancreatic

Phase: II

Investigator: Ramirez, Robert

NCTID: NCT04924075

Protocol No: VICCMD2132

Learn More

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

Disease Sites: Not Available

Phase: II

Investigator: Not Available

NCTID: NCT04546399

Protocol No: COGAALL1821

Learn More

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Head/Neck

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.

Disease Sites: Head/Neck

Phase: II/III

Investigator: Topf, Michael

NCTID: NCT04333537

Protocol No: NRGHN006

Learn More

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Pancreatic

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may be safe, tolerable and/or more effective than radiation therapy alone in treating patients with locally advanced pancreatic cancer.

Disease Sites: Pancreatic

Phase: I/II

Investigator: Cardin, Dana

NCTID: NCT04172532

Protocol No: NCIGIP10366

Learn More

Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck

Multiple Cancer Types

The goal of this clinical trial is to learn if the combination of the drug cemiplimab along with a short course of radiation therapy called Quad Shot can be successfully given in several rounds to elderly or frail patients with head and neck skin cancers. The main question it aims to answer is:

\- Can care providers successfully deliver at least 6 rounds of cemiplimab and 3 rounds of Quad Shot radiation to patients?

Patients will:

* Be given cemiplimab every 3 weeks for a total of up to 8 doses
* Be given Quad Shot radiation (four treatments over two days) every 3 weeks for a total of up to 4 rounds

Disease Sites: Dermatologic, Head/Neck, Supportive Care

Phase: N/A

Investigator: Murphy, Barbara

NCTID: NCT07869823

Protocol No: VICC-VDHAN23130

Learn More

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Multiple Cancer Types

The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+ cancers.

Disease Sites: Breast, Phase I

Phase: I

Investigator: Rosenthal, Eben

NCTID: NCT06828588

Protocol No: VICCBREP24601

Learn More